WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025
The Asia-Pacific Biopharma Excellence Awards honor companies annually that have exhibited outstanding performance and achievement in the biopharmaceutical sector. These accolades underscore WuXi XDC's leadership, innovation, and fully integrated CRDMO platform, empowering global clients from early discovery to commercial manufacturing.
Industry-leading development and manufacturing capabilities (Best ADC CDMO in Asia & China): WuXi XDC's state-of-the-art facilities and global dual-sourcing strategy enable seamless CMC development and GMP manufacturing, accelerating the timeline while ensuring a high success rate and regulatory excellence.
Innovation in Discovery & Development (Best ADC CRO in Asia): WuXi XDC's proprietary conjugation and payload-linker technologies, along with the incorporation of external technologies through partnerships, drive ADC and XDC discovery, optimization, and IND-enabling studies, expediting clients' clinical advancement.
Pioneering ADC Technology (Best ADC Platform Technology): Through next-generation payload-linker innovations and site-specific conjugation technologies, from internal development and external partnership, WuXi XDC provides clients with diversified technology suites to advance ADC and XDC developments.
Dr. Jimmy Li, CEO of WuXi XDC, commented: "We are honored to receive these prestigious awards, which not only reaffirm our team's relentless pursuit of excellence and innovation in the ADC field but also underscore our dedication to delivering world-class services that empower our clients to bring novel therapies to patients worldwide. They are a testament to the hard work and dedication of every WuXi XDC employee – their relentless efforts that have made this milestone possible. It also belongs to our valued partners, whose trust and collaboration have driven our collective success. Looking ahead, WuXi XDC will continue to support our clients and advance the innovation and progress of the global bioconjugate industry."
These awards follow WuXi XDC's recent recognition at the 2024 World ADC Awards, where the company was named Best CDMO Winner for the second consecutive year, further solidifying its leadership position in the global ADC industry. As the ADC market continues to experience sustainable growth, WuXi XDC relentlessly committed to advancing its technological capabilities and expanding its service offerings to meet clients' evolving needs.
About WuXi XDC
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com
WuXi XDC Contacts
Investor: wuxixdc.ir@wuxibiologics.com Media: wuxixdc_pr@wuxibiologics.com BD: wuxixdc_info@wuxibiologics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-xdc-wins-multiple-awards-at-asia-pacific-biopharma-excellence-awards-2025-302400791.html
SOURCE WuXi XDC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
AP Top Extended Financial Headlines at 1:16 a.m. EDT
Asian shares are mostly trading higher after U.S. stocks hit another record Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
36 minutes ago
- Forbes
Philippine Tycoon Joselito Campos Del Monte Pacific's U.S. Unit Files For Bankruptcy
Del Monte branded cans of pineapple chunks sit on a shelf in a grocery store in Manila, the ... More Philippines, on Friday, Oct. 11, 2013. Del Monte Pacific—the canned food producer controlled by Philippine food-to-pharmaceuticals tycoon Joselito Campos and his siblings—said it will deconsolidate its U.S. subsidiary, which has filed for bankruptcy. Del Monte Pacific announced the deconsolidation of Del Monte Foods Holdings Ltd. (DMFHL) late Wednesday in a statement to the stock exchanges of Singapore and the Philippines where shares of the Manila-based company are listed. 'The company is in the process of assessing the financial impact that its deconsolidation of DMFHL might have on the Del Monte Pacific Group,' Del Monte Pacific said in the statement. 'Updates on such financial implications will be provided in due course.' Del Monte Pacific—known for its canned pineapple and fruit cocktail as well as its sauces—said its net investment in DMFHL was at $579 million as of Jan. 31. In addition, Del Monte Pacific and its affiliates have $169 million in net receivables from DMFHL and its units, including Del Monte Foods Inc. Del Monte Pacific shares tumbled 8.2% in morning trading in Singapore, heading for its second day of decline. 'The value to be impaired will be determined after the audit,' Del Monte Pacific said. 'Updates on the financial impacts will be provided in due course.' Del Monte Philippines, along with its Asian and international business, continue to perform well and its operation will remain uninterrupted, it added. Del Monte Pacific said it lost control of DMFHL in June after skipping debt payments. As a consequence, creditors appointed a majority of directors to the boards of DMFHL and its units while 25% of Del Monte Pacific's equity in DMFHL was transferred to the lenders. DMFHL newly constituted board entered into a restructuring agreement with a group of lenders. Under the agreement, all or substantially all of the company's assets and its subsidiaries would be sold through Chapter 11 proceedings in the U.S. As part of the Chapter 11 proceeding, DMFHL and its subsidiaries will have access to approximately $912.5 million in 'debtor in possession' financing to fund their ongoing operations, Del Monte Pacific said. Del Monte Pacific is among the assets owned by Campos and his siblings, who inherited Unilab, one of the Philippines' largest pharmaceutical companies that was co-founded by their late father, Jose Campos, almost eight decades ago. The Campos family is among the wealthiest in the Philippines with a net worth of $940 million, according to Forbes Asia.
Bloomberg
36 minutes ago
- Bloomberg
Sega Corporation's Utsumi on Business Outlook & Strategy
Shuji Utsumi, President & COO of Sega Corporation, and CEO of Sega America & Europe, discusses his view for the company's business plans and growth strategy, and his plans to revive the gaming giant. He says he was impressed with Nintendo Switch 2 sales volumes and "hope the trend continues" to boost business for gaming product makers like Sega. He joins from the sidelines of startup conference, IVS, in Kyoto, and speaks with Haslinda Amin on "Insight with Haslinda Amin". (Source: Bloomberg)
